MHRA authorizes Lilly's orforglipron, a European first

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) authorized orforglipron, sold as Foundayo, on August 10, 2026, making Britain the first country in Europe to license the once-daily GLP-1 tablet for both weight management and type 2 diabetes ^[1].

The UK authorization covers adults with a body mass index of 30 or above, or a BMI between 27 and 30 with at least one weight-related health condition, used alongside a reduced-calorie diet and increased physical activity ^[1]. A separate indication covers improving blood sugar control in people whose type 2 diabetes is not adequately controlled ^[1].

"Following rigorous assessment of orforglipron's safety, quality, and effectiveness, we are pleased to be the first regulator in Europe to authorise this tablet for weight management and type 2 diabetes," said Julian Beach, the MHRA's Executive Director of Healthcare Quality and Access ^[1]. He added that orforglipron is prescription-only and that the agency "will keep the safety and effectiveness of orforglipron under close review," as it does with all GLP-1 receptor agonists ^[1].

What the label says

The tablet is taken once a day at any time, with no food or water restrictions ^[1]. That last detail is the practical difference from Rybelsus, the oral form of semaglutide, which requires a fasting window ^[2].

Dosing starts at 0.8 mg and steps up through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg, with a minimum of one month at each level ^[1]. The MHRA lists the most common side effects as nausea, constipation, diarrhea, vomiting, indigestion and abdominal pain ^[1] — the same gastrointestinal pattern seen across the GLP-1 class.

Orforglipron is a small-molecule GLP-1 receptor agonist rather than a peptide. Peptide drugs such as semaglutide and tirzepatide are broken down in the gut, which is why they are normally injected; a small molecule survives digestion intact ^[2].

Where the US stands

American patients are ahead of British ones on access, at least in one indication. The FDA approved orforglipron for obesity in April 2026, and Lilly submitted the drug to the FDA for type 2 diabetes during the second quarter of 2026 ^[2]. The sources do not give an expected FDA decision date for the diabetes filing, so that timing is not yet known.

In the UK, authorization is not the same as availability. Foundayo is not currently available through the National Health Service, and NHS use requires a separate evaluation by the National Institute for Health and Care Excellence (NICE) ^[1]. Lilly began UK supply on August 24 through private prescription only, with indicated private pricing of £100 to £120 per month ^[2]. The sources do not report a US list price or cash-pay price for comparison.

Why it matters for patients

For US readers, the main significance is competitive rather than clinical. A second major regulator reviewing the same data and reaching the same conclusion adds to the evidence base behind an oral GLP-1 that is already available here for obesity ^[1][2].

The route of administration is the real point of difference. A daily pill with no fasting window removes the injection barrier for people who decline needles ^[2]. Whether that translates into better long-term results depends on individual response and on side effects, which the MHRA lists as mostly digestive ^[1].

One caution applies on both sides of the Atlantic: the MHRA stressed that all GLP-1 medicines are prescription-only, obtainable only from a registered pharmacy with a prescription, and that buying them from unregulated sellers "carries serious health risks" ^[1]. Illicit supply remained a live safety issue through August, with Lilly bringing six US lawsuits against sellers of unapproved retatrutide, a drug that is still investigational ^[2].

What happens next

The NICE appraisal of orforglipron remains open. NICE has requested further information from Lilly after its first committee meeting and has not set a date for a second review; the appraisal listing carries an expected publication date of November 18, 2026 ^[2]. Full UK prescribing documents were due on the MHRA products website within seven days of the August 10 approval ^[1].